

## Recombinant Human PCSK9 (C-6His)

Catalog No: CA83

<b>Description</b>	Recombinant Human Proprotein Convertase Subtilisin/Kexin Type 9 is produced by our Mammalian expression system and the target gene encoding Gln31-Gln692(Val474Ile,Gly670Glu) is expressed with a 6His tag at the C-terminus.
<b>Source</b>	Human Cells
<b>Alternative name</b>	Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1
<b>Accession No.</b>	Q8NBP7
<b>Predicted Molecular Weight</b>	13.77&58.2kDa
<b>AP Molecular Weight</b>	19&60kDa, reducing conditions.
<b>Formulation</b>	Supplied as a 0.2 µm filtered solution of 50mM HEPES, 150mM NaCl, 20% Glycerol, pH 7.4.
<b>Quality Control</b>	Purity: Greater than 95% as determined by reducing SDS-PAGE. Endotoxin: Less than 0.1 ng/µg (1 IEU/µg) as determined by LAL test.
<b>Shipping</b>	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
<b>Storage</b>	Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles.

### Background

Human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER, the pro domain and mature chain secrete together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and plays a major regulatory role in cholesterol homeostasis. Inhibition of PCSK9 function by preventing PCSK9/LDLR interaction is currently being explored as a means of lowering cholesterol levels. PCSK9 also binds to apolipoprotein receptor 2 (ApoER2), and play a role in the neural development.

### SDS-Page

